FindMyKOL
Clinical trialNCT00288626CompletedPhase 2Interventional

High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study

SponsorNational Institute of Allergy and Infectious Diseases (NIAID)Enrollment25Relapsing-Remitting Multiple Sclerosis
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to determine the effectiveness of a new treatment for multiple sclerosis (MS), a serious disease in which the immune system attacks the brain and spinal cord. MS can be progressive and severe and lead to significant disability. The study treatment involves the use of high-dose chemotherapeutic drugs to suppress the immune system. The participant's own (autologous) blood-forming (hematopoietic, CD34+) stem cells are collected before the chemotherapy is given, and then transplanted back into the body following treatment. Transplantation of autologous hematopoietic stem cells is required to prevent very prolonged periods of low blood cell counts after the high-dose chemotherapy.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

  • Annette Wundes, MD

    Department of Neurology, University of Washington

    Study Chair
    clinicaltrials.gov ↗
  • George E. Georges, MD

    Fred Hutchinson Cancer Research Center, Clinical Research Division, University of Washington

    Study Chair
    clinicaltrials.gov ↗
  • George H. Kraft, MD

    Departments of Neurology and Rehabilitation Medicine, University of Washington

    Study Chair
    clinicaltrials.gov ↗
  • George J. Hutton, MD

    The Maxine Messinger Multiple Sclerosis Clinic, The Methodist Hospital, Baylor College of Medicine

    Study Chair
    clinicaltrials.gov ↗
  • James D. Bowen, MD

    Multiple Sclerosis Center, Swedish Neuroscience Institute, Seattle, Washington

    Study Chair
    clinicaltrials.gov ↗
  • Michael K. Racke, MD

    Department of Neurology, Ohio State University Medical Center

    Study Chair
    clinicaltrials.gov ↗
  • Richard A. Nash, MD

    Blood and Marrow Transplant Program, Colorado Blood Cancer Institute, Presbyterian/St. Luke's Medical Center, Denver

    Study Chair
    clinicaltrials.gov ↗
  • Steven M. Devine, MD

    Department of Hematology and Oncology, Ohio State University Medical Center

    Study Chair
    clinicaltrials.gov ↗
  • Uday Popat, MD

    Department of Blood and Marrow Transplantation, University of Texas, M.D. Anderson Cancer Center

    Study ChairKOL profile →
    clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Ohio State University School of Medicine

    Columbus, Ohio, United States

  • Baylor College of Medicine

    Houston, Texas, United States

  • M.D. Anderson Cancer Center; Transplant Site, Please Contact Baylor College of Medicine

    Houston, Texas, United States

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

CarmustineGranulocyte-colony stimulating factor and prednisone
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Jul 2006
Primary completion
30 Nov 2015
Completion
30 Nov 2015
Last update posted
19 Sept 2017
Registered enrollment
25
Registry id
NCT00288626
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.